(60 days)
The CELL-DYN 3500 and the CELL-DYN 3700 Systems are automated, multi-parameter hematology analyzers intended to classify the following formed elements of EDTA anticoagulated blood including: White Blood Cell Parameters: WBC -- White Blood Cell or Leukocyte Count, NEU -- Neutrophil Absolute Count, %N -- Neutrophil Percent, LYM -- Lymphocyte Absolute Count, %L -- Lymphocyte Percent, MONO -- Monocyte Absolute Count, %M -- Monocyte Percent, EOS -- Eosinophil Absolute Count, %E -- Eosinophil Percent, BASO -- Basophil Absolute Count, %B -- Basophil Percent; Red Blood Cell Parameters: RBC -- Red Blood Cell or Erythrocyte Count, HCT -- Hematocrit, MCV -- Mean Corpuscular Volume, RDW -- Red Cell Distribution Width; Hemoglobin Parameters: HGB -- Hemoglobin Concentration, MCH -- Mean Corpuscular Hemoglobin, MCHC -- Mean Corpuscular Hemoglobin Concentration; Platelet Parameters: PLT -- Platelet Count, MPV -- Mean Platelet Volume, *PDW -- Platelet Distribution Width, *PCT -- Plateletcrit; Reticulocyte Parameters: RETC -- Reticulocyte Concentration, %R -- Reticulocyte Percent of RBC Count, IRF -- Immature Reticulocyte Fraction. * These parameters are provided for laboratory use only and are not reportable in the US.
The CELL-DYN 3500 and the CELL-DYN 3700 Systems have four main modules: 1) the Analyzer, which aspirates, dilutes and analyzes each whole blood specimen 2) the Sample Loader, which automatically identifies, mixes, and presents specimens for processing 3) the Data Station, which controls all system processing and provides the primary operator interface with the system and; 4) the Color Printer, which generates reports automatically or on demand. The analyzer counts, sizes and classifies blood cells by the combination of methods: Laser Optical Light Scatter, Impedance, and Absorption Spectrophotometry. The IRF is derived from the data measured for the Reticulocyte parameters. The CELL-DYN 3500 and the CELL-DYN 3700 Systems use a Helium-Neon laser as the optical light source. The Optical Bench detects light in the form of scatter from blood cell surfaces and internal structures. For the reticulocyte parameters, an off-line dilution of blood and Reticulocyte Reagent is prepared and stained for 15 minutes. The dilution is aspirated and the reticulocytes are counted in the WOC channel. Data are collected for scatter (0°, 10°, and 90°) as each cell passes through the laser beam. The CELL-DYN 3500 and the CELL-DYN 3700 Systems report Reticulocyte % and Absolute Count. The IRF is a fraction of the total reticulocyte absolute count. The CELL-DYN 3500 and the CELL-DYN 3700 Systems are designed to analyze EDTA-anticoagulated whole blood specimens and report the additional Immature Reticulocyte Parameter.
Here's an analysis of the acceptance criteria and study details for the CELL-DYN 3500 and 3700 Systems with Immature Reticulocyte Fraction (IRF), based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The provided text states that the study evaluated "background, accuracy, precision, linearity, and carryover" and that the "accuracy, precision, and linearity data shows performance to manufacturer's specifications." However, it does not explicitly list the quantitative acceptance criteria for these aspects, nor does it provide quantitative performance results. It only states that the device met the manufacturer's specifications.
Therefore, a table cannot be fully populated with specific numerical acceptance criteria and performance data from the given document.
2. Sample Size Used for the Test Set and Data Provenance
- Test Set Sample Size: Not explicitly stated as a single number. The study was conducted at "two field clinical sites and one internal site," collecting data for "background, accuracy, precision, linearity, and carryover." It's implied that various samples were used to assess these different aspects, but a total sample size for the test set is not provided.
- Data Provenance:
- Country of Origin: United States (Scottsdale, AZ; Phoenix, AZ; Santa Clara, CA).
- Retrospective or Prospective: Not explicitly stated. Given that data was "collected" at clinical and internal sites for the purpose of showing substantial equivalence, it suggests a prospective, controlled study design, but this is an inference.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
There is no information provided regarding experts being used to establish ground truth. The study appears to be a comparative effectiveness study against a predicate device (CELL-DYN 4000 System) and against manufacturer's specifications, rather than a study relying on expert human interpretation for ground truth. The devices are automated hematology analyzers, meaning their measurements are compared against other automated methods or predefined analytical standards.
4. Adjudication Method for the Test Set
Not applicable. The study is comparing automated analytical results against a predicate automated device and manufacturer's specifications, not against human interpretation that would require adjudication.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
No, an MRMC comparative effectiveness study was not done. This study concerns an automated hematology analyzer, not an AI system assisting human readers. The concept of "human readers improve with AI vs without AI assistance" is not relevant to this submission.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Yes, a standalone study was done. The CELL-DYN 3500 and 3700 Systems are automated hematology analyzers. The study evaluated the performance of these devices (the "algorithm only") in reporting parameters including the Immature Reticulocyte Fraction (IRF) in comparison to a predicate automated device and manufacturer specifications.
7. The Type of Ground Truth Used
The ground truth for this study was established through:
- Comparison to a Predicate Device: The CELL-DYN 4000 System (510(k) #971152/S1). The study aimed to demonstrate "substantial equivalence" to this predicate device for the IRF parameter.
- Manufacturer's Specifications: The device's "accuracy, precision, and linearity data shows performance to manufacturer's specifications." This implies that the manufacturer had internal analytical standards that the device was evaluated against.
Therefore, the ground truth is analytical accuracy and precision relative to a legally marketed predicate device and internal performance criteria.
8. The Sample Size for the Training Set
Not applicable. This document describes the validation of a medical device's performance, not the training of a machine learning model. Therefore, there is no "training set" in the context of AI/ML.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set mentioned or implied in the context of AI/ML. The device's underlying principles are based on established analytical methods (Laser Optical Light Scatter, Impedance, and Absorption Spectrophotometry) rather than learned patterns from a training dataset.
{0}------------------------------------------------
JUL - 9 1999
16. 510(k) Summary
CELL-DYN 3500 System and the CELL-DYN 3700 System with Immature Reticulocyte Fraction (IRF)
| Submitted by: | Abbott Laboratories5440 Patrick Henry DriveSanta Clara, CA 95054 |
|---|---|
| Contact Person: | Michelle B. RoedingPhone: 408 567-3781Fax:408 982-4863 |
| Date Prepared: | May 7, 1999 |
| Proprietary Name: | CELL-DYN 3500 System with ImmatureReticulocyte Fraction (IRF)CELL-DYN 3700 System with ImmatureReticulocyte Fraction (IRF) |
| Common Name: | Automated Hematology Analyzers |
| Classification Name: | Automated Differential Cell Counter (21 CFR 864.5220) |
| Predicate Device: | CELL-DYN 4000 System, 510(k) #971152/S1 |
K991605
510(k) Notification
{1}------------------------------------------------
16. 510(k) Summary (cont'd)
CELL-DYN 3500 System and the CELL-DYN 3700 System with Immature Reticulocyte Fraction (IRF)
Intended Use
The CELL-DYN 3500 and the CELL-DYN 3700 Systems are automated, multi-parameter hematology analyzers intended to classify the following formed elements of EDTA anticoagulated blood including:
| White Blood Cell Parameters: | Red Blood Cell Parameters: |
|---|---|
| WBC -- White Blood Cell or Leukocyte Count | RBC -- Red Blood Cell or Erythrocyte Count |
| NEU -- Neutrophil Absolute Count | HCT -- Hematocrit |
| %N -- Neutrophil Percent | MCV -- Mean Corpuscular Volume |
| LYM -- Lymphocyte Absolute Count | RDW -- Red Cell Distribution Width |
| %L -- Lymphocyte Percent | |
| MONO -- Monocyte Absolute Count | Hemoglobin Parameters: |
| %M -- Monocyte Percent | HGB -- Hemoglobin Concentration |
| EOS -- Eosinophil Absolute Count | MCH -- Mean Corpuscular Hemoglobin |
| %E -- Eosinophil Percent | MCHC -- Mean Corpuscular Hemoglobin |
| BASO -- Basophil Absolute Count | Concentration |
| %B -- Basophil Percent | |
| Platelet Parameters: | Reticulocyte Parameters: |
| PLT -- Platelet Count | RETC -- Reticulocyte Concentration |
| MPV -- Mean Platelet Volume | %R -- Reticulocyte Percent of RBC Count |
| *PDW -- Platelet Distribution Width | IRF -- Immature Reticulocyte Fraction |
| *PCT -- Plateletcrit |
- These parameters are provided for laboratory use only and are not reportable in the US.
Device Description:
The CELL-DYN 3500 and the CELL-DYN 3700 Systems have four main modules: 1) the Analyzer, which aspirates, dilutes and analyzes each whole blood specimen 2) the Sample Loader, which automatically identifies, mixes, and presents specimens for processing 3) the Data Station, which controls all system processing and provides the primary operator interface with the system and; 4) the Color Printer, which generates reports automatically or on demand.
{2}------------------------------------------------
16. 510(k) Summary (cont'd)
CELL-DYN 3500 System and the CELL-DYN 3700 System with Immature Reticulocyte Fraction (IRF)
Device Description (cont'd):
The analyzer counts, sizes and classifies blood cells by the combination of methods: Laser Optical Light Scatter, Impedance, and Absorption Spectrophotometry. The IRF is derived from the data measured for the Reticulocyte parameters. The CELL-DYN 3500 and the CELL-DYN 3700 Systems use a Helium-Neon laser as the optical light source. The Optical Bench detects light in the form of scatter from blood cell surfaces and internal structures.
For the reticulocyte parameters, an off-line dilution of blood and Reticulocyte Reagent is prepared and stained for 15 minutes. The dilution is aspirated and the reticulocytes are counted in the WOC channel. Data are collected for scatter (0°, 10°, and 90°) as each cell passes through the laser beam.
The CELL-DYN 3500 and the CELL-DYN 3700 Systems report Reticulocyte % and Absolute Count. The IRF is a fraction of the total reticulocyte absolute count. The CELL-DYN 3500 and the CELL-DYN 3700 Systems are designed to analyze EDTA-anticoagulated whole blood specimens and report the additional Immature Reticulocyte Parameter.
Similarities and Differences:
The CELL-DYN 3500 and the CELL-DYN 3700 Systems with IRF, and the CELL-DYN 4000 System are similar in that the systems use impedance for counting and sizing RBCs. The Reticulocyte Reagent enables both the CELL-DYN 3500 and the CELL-DYN 3700 Systems with IRF and the CELL-DYN 4000 System to count and classify mature and immature reticulocytes. The CELL-DYN 3500 and the CELL-DYN 3700 Systems with IRF and the CELL-DYN 4000 System with IRF, enumerate reticulocytes in EDTA-anticoagulated whole blood using optical laser scatter. They are different in that CELL-DYN 3500 and the CELL-DYN 3700 Systems with IRF specimens are externally stained in an off-line preparation step with New Methylene Blue while the CELL-DYN 4000 System with IRF automatically dilutes the specimen with a fast acting proprietary dye that requires no incubation prior to measurement.
{3}------------------------------------------------
16. 510(k) Summary (cont'd)
CELL-DYN 3500 System and the CELL-DYN 3700 System with Immature Reticulocyte Fraction (IRF)
Equivalency Data:
The data compiled to support the claim that the CELL-DYN 3500 and the CELL-DYN 3700 Systems IRF are substantially equivalent to the Abbott CELL-DYN 4000 System include background, accuracy, precision, linearity, and carryover. The data supports the claim that the CELL-DYN 3500 and the CELL-DYN 3700 Systems IRF parameters are substantially equivalent to the Abbott CELL-DYN 4000 System IRF parameter. The accuracy, precision, and linearity data shows performance to manufacturer's specifications. Data was collected at Scottsdale Health Care - Shea, Scottsdale, AZ; VAMC, Phoenix, AZ; and an internal Abbott Diagnostics Division site.
Conclusion:
The CELL-DYN 3500 and the CELL-DYN 3700 Systems IRF demonstrate substantial equivalence to the predicate device.
{4}------------------------------------------------
17. Financial Disclosure
Data was collected from two field clinical sites and one internal site.
The two clinical sites were Scottsdale Health Care - Shea, Scottsdale, Arizona and Veteran's Affairs Medical Center (VAMC), Phoenix, Arizona. Scottsdale Health Care was paid $14,000 on 12/11/98, VAMC was paid $5,984.78 on 12/9/98. Neither site's reimbursement exceeded $25,000.00 for this clinical study.
The internal Abbott Diagnostics Division site in Santa Clara, CA also collected data for this clinical study. Financial disclosure is not applicable as there was no payment involved.
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features the department's name encircling a symbol. The symbol consists of three stylized human profiles facing right, stacked on top of each other. The profiles are rendered in a flowing, wave-like design.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUL - 9 1999
Ms. Michelle B. Roeding Regulatory Affairs Supervisor Abbott Laboratories Diagnostic Division 5440 Patrick Henry Drive Santa Clara, California 95054
- K991605 Re:
Trade Name: CELL-DYN 3500 System with Immature Reticulocyte Fraction CELL-DYN 3700 System with Immature Reticulocyte Fraction Regulatory Class: III Product Code: GKZ Dated: May 7, 1999 Received: May 10, 1999
Dear Ms. Roeding:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition. FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{6}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510/k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
Indications For Use Statement
K980614/A1 510(k): CELL-DYN 3500 System with Immature Reticulocyte Fraction Device Name: CELL-DYN 3700 System with Immature Reticulocyte Fraction
Indications for Use: The CELL-DYN 3500 and the CELL-DYN 3700 Systems are automated, multiparameter hematology analyzers intended to classify the following formed elements of EDTA anticoagulated blood:
| WBC -- White Blood Cell or Leukocyte Count | RBC -- Red Blood Cell or Erythrocyte Count |
|---|---|
| NEU -- Neutrophil Absolute Count | HCT - Hematocrit |
| %N -- Neutrophil Percent | MCV -- Mean Corpuscular Volume |
| LYM -- Lymphocyte Absolute Count | RDW -- Red Cell Distribution Width |
| %L -- Lymphocyte Percent | HGB -- Hemoglobin Concentration |
| MONO -- Monocyte Absolute Count | MCH -- Mean Corpuscular Hemoglobin |
| %M -- Monocyte Percent | MCHC -- Mean Corpuscular Hemoglobin |
| EOS -- Eosinophil Absolute Count | Concentration |
| %E -- Eosinophil Percent | RETC -- Reticulocyte Concentration |
| BASO -- Basophil Absolute Count | % RETC -- Reticulocyte Concentration |
| %B -- Basophil Percent | IRF -- Immature Reticulocyte Fraction |
| PLT -- Platelet Count | *PDW -- Platelet Distribution Width |
| MPV -- Mean Platelet Volume | *PCT -- Plateletcrit |
- These parameters are provided for laboratory use only and are not reportable in the US.
PLEASE DO NOT WRITE BELOW THIS LINE CONTINUE ON ANOTHER PAGE IF NEEDED Concurrence of CDRH, Office of Device Evaluation (ODE)
Alkem
(Division Sign-Off)/
Sign-on aboratory Devices Nag 1605
Clinical
(Division of Clinical 510(k) Number
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use
§ 864.5220 Automated differential cell counter.
(a)
Identification. An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.(b)
Classification. Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”